Beacon Pharmaceuticals PLC is a Bangladeshi pharmaceutical company that develops generic version of medications.

This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (July 2019)

Quick Facts Company type, Traded as ...

Beacon Pharmaceuticals PLC

Company type	Public
Traded as	DSE: BEACONPHAR, CSE: BEACONPHAR
Industry	Pharmaceutics Biotechnology
Founded	2006; 18 years ago (2006)
Headquarters	Dhaka , Bangladesh
Key people	Mohammad Ebadul Karim Bulbul, (MD)
Products	Sofosvel, Darvoni, Tagrix, Crizonix, Daclavir, Soforal, Afanix, Axinix, Brigaix, Baricinix, Cabozanix, Dasanix, Hernix, Elbonix, Ibrutix, Lenvanix, Palbonix, Regonix, Tofacinix, and Wedica
Revenue	US$56 million (2019)
Operating income	US$27 million (2019)
Net income	US$4 million (2019)
Total assets	US$100 million (2021
Number of employees	4,000 (2021)
Website	beaconpharma.com.bd

Close

Beacon manufactures more than 200 generic drugs and 65 oncology products. Beacon is the first company in Bangladesh to start export of cancer drugs.^[1][2] The company is exporting its products to Asia, Africa, Europe and Latin America. Beacon is public limited company listed in Dhaka & Chittagong stock exchange. About 2000 people are working in this company.^[3][4][5]

Beacon has introduced a number of global first generics.^[6]

The company's commercially available products include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib, and trelagliptin.

BEACON Medicare Limited(BML)^[7] is the exclusive global marketing & distribution partner of Beacon Pharmaceuticals Limited.